Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Allogeneic stem cell therapy; Antithymocyte globulin; Busulfan; Clofarabine; Mycophenolate mofetil; Mycophenolate mofetil; Rituximab; Tacrolimus; Tacrolimus
- Indications B-cell lymphoma; Graft-versus-host disease; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 13 Nov 2019 Planned primary completion date changed from 25 Oct 2019 to 1 May 2020.
- 07 May 2019 Planned End Date changed from 1 Oct 2020 to 25 Oct 2020.
- 07 May 2019 Planned primary completion date changed from 1 Oct 2019 to 25 Oct 2019.